3 Houston innovators to know right now

who's who

This week's roundup of Houston innovators includes Phillip Yates of Equiliberty, Meagan Pitcher of Bairitone Health, and Moody Heard of Builtforce. Photos courtesy

Editor's note: InnovationMap regularly introduces its readers to a handful of Houston innovators recently making headlines with news of innovative technology, investment activity, and more. Our first January batch includes three innovators across social impact, health care, and more.

Phillip Yates, CEO of Equiliberty

Phillip Yates joins the Houston Innovators Podcast to share why 2025 is the year of launch for Equiliberty. Photo courtesy of Equiliberty

For Phillip Yates, this year will be the year of launch. The attorney-turned-entrepreneur has been working on his fintech platform, Equiliberty, for years now, but come the first half of 2025, it's go time.

"We're going to release our technology in Q2 of this year, and we're looking to commercialize it by the end of this year," Yates says on the Houston Innovators Podcast.

The platform connects users with resources to build wealth. Yates, along with his co-founders, Rachel Howard and Cody Bailey, created the company with the mindset that people with lower financial means can take control of their own financial success — in a way that doesn't take away from anyone else. Continue reading.

Meagan Pitcher, co-founder and CEO of Bairitone Health

Meagan Pitcher, co-founder and CEO of Bairitone Health, joins the Houston Innovators Podcast. Photo courtesy of Bairitone

There's a slew of treatment options for people living with sleep apnea. But, the bigger problem, as Meagan Pitcher realized during her time at the Texas Medical Center's Biodesign program, is that there's no easy way to reliably diagnose and determine a treatment plan for patients.

"We saw all of the companies trying to solve the problem of making the airway collapse less or make the air way wider — it might be surgery, might be medication, or nerve stimulation," Pitcher says on the Houston Innovators Podcast. "One of the things we found was that it was really hard to match a patient with sleep apnea with a good treatment for them. One of the reasons is it's hard to get an understanding of where the individual's site of collapse is as sleep medicine is currently practiced."

As Pitcher went through the TMC Biodesign program, she teamed up with her co-founders — CTO Onur Kilicand and CMO Britt Cross — to find a solution, and together they developed Bairitone Health. The company's technology provides at-home medical imaging using sonar sensing. The non-invasive device has the potential to replace the current standard of care, which is a surgical procedure. Continue reading.

Moody Heard, CEO of BuildForce

Houston-based Buildforce is developing a technology to better connect contractors and the trade professionals they employ. Photo courtesy of Buildforce

Houston-based Buildforce announced it has acquired Ladder, which is a Y Combinator-backed, technology-enabled construction labor marketplace.

The acquisition is part of Buildforce’s expansion plans into the southeastern U.S. and during a time of increased demand for skilled construction talent. Buildforce will work to leverage the Ladder customer base of over 200 customers across six states, as well as its extensive electrician network of over 10,000 pre-screened electricians, which is the largest in the Southeast.

“There are two major problems plaguing the construction labor market,” Moody Heard, co-founder and CEO of Buildforce, says in a news release. “One, the project-based nature of construction work means tradesmen are constantly ‘working themselves out of a job’, meaning high employee turnover. And two, the industry is experiencing a secular decline in the supply of tradesmen relative to surging demand.” Continue reading.

Meagan Pitcher, co-founder and CEO of Bairitone Health, joins the Houston Innovators Podcast. Photo courtesy of Bairitone

Promising Houston sleep tech startup readies for big year of growth, work toward FDA clearance

HOUSTON INNOVATORS PODCAST EPISODE 268

There's a slew of treatment options for people living with sleep apnea. But, the bigger problem, as Meagan Pitcher realized during her time at the Texas Medical Center's Biodesign program, is that there's no easy way to reliably diagnose and determine a treatment plan for patients.

"We saw all of the companies trying to solve the problem of making the airway collapse less or make the air way wider — it might be surgery, might be medication, or nerve stimulation," Pitcher says on the Houston Innovators Podcast. "One of the things we found was that it was really hard to match a patient with sleep apnea with a good treatment for them. One of the reasons is it's hard to get an understanding of where the individual's site of collapse is as sleep medicine is currently practiced."

As Pitcher went through the TMC Biodesign program, she teamed up with her co-founders — CTO Onur Kilicand and CMO Britt Cross — to find a solution, and together they developed Bairitone Health. The company's technology provides at-home medical imaging using sonar sensing. The non-invasive device has the potential to replace the current standard of care, which is a surgical procedure.



This year, the company joined Activate Houston's inaugural cohort as the lone biotech company. Activate, which announced its expansion to Houston in 2023, helps hardtech founders develop and grow their companies from bench to commercialization, though it mostly focuses on industrial or climatetech innovators. In addition to this accomplishment, Bairitone Health was among the 2024 Houston Innovation Awards finalists.

While 2024 was successful for the company, next year should bring even more milestones for Bairitone, Pitcher says, including a seed round of funding that will support the growth of their team, fund early testing, and fuel Baritone's path toward FDA clearance.

"2025 is going to be a big year for Bairitone, especially around solidifying our regulatory plan. The device we're making is really low risk — we're not putting anything into the body, and we're potentially replacing a surgical procedure," Pitcher says. "We've always hypothesized that we'll have a 510(k) clearance with the FDA, but we're moving toward having our first meeting with the FDA to solidify those plans."

Bairitone's journey so far has been a uniquely Houston story, as Pitcher acknowledges.

"I really love Houston — especially for med tech. The medical center is just awesome, you have all these brilliant people coming in from the entire world to work at these institutions," Pitcher says. "It's kind of because of this atmosphere of excellence around health care, innovation, open mindedness, and collaboration — those are reasons why I really love working in Houston."

The inaugural Activate Houston cohort has 11 fellows across energy, materials, life sciences, space, and other sectors. Photo via activate.org

Hardtech fellowship names 11 innovators to inaugural Houston cohort

ready for activation

A national hardtech-focused organization has named its 2024 batch of innovators, which includes the inaugural Houston-based cohort.

Activate named 62 fellows and 50 companies for is latest class, which spans Berkley, California — where the organization is based, Boston, New York, and Houston. Additionally, Activate Anywhere, the program's virtual and remote cohort, was named. According to Activate, it received over 1,000 applicants.

“People, not ideas alone, move the world forward. It is through the drive and determination of brilliant scientists and engineers that we are witnessing true progress,” says Activate CEO Cyrus Wadia in a news release. “Our current Activate Fellows and alumni are already pioneering innovative solutions that make a measurable difference. We’re thrilled to support the next 62 visionaries who will lead the charge in addressing our most urgent issues through groundbreaking science and technology.”

It's the first year Activate has hosted a Houston-based cohort. The organization initially announced its expansion early last year. The inaugural cohort has 11 fellows across energy, materials, life sciences, space, and other sectors.

The named Houston fellows selected for the 2024 class include:

  • Krish Mehta, founder and CEO of Phoenix Materials, a company that decarbonizes concrete using industrial waste.
  • Gabriel Cossio, founder and CEO of Nanoscale Labs, which is developing a high-throughput and low-cost nanomanufacturing system.
  • Matthew McDermott, founder and CEO of Refound Materials, a materials technology company developing more efficient synthesis recipes for accelerated materials discovery.
  • Alec Ajnsztajn, founder and CEO of Coflux Purification, a company that's creating a product that allows industries and water providers to cheaply remove forever chemicals to provide safe drinking water at a fraction of current energy use.
  • Ryan DuChanois and Yang Xia , co-founders of Solidec, a Houston-based startup redefining chemical manufacturing.
  • Meagan Pitcher, co-founder and CEO of Bairitone Health, which brings advanced imaging diagnostics into the home environment.
  • Wei Meng, co-founder and CEO of LumiStrain, a startup offering novel technology for mechanical strain mapping.
  • Sonia Dagan of Atolla Tech, which is developing a lidar and machine-learning algorithm for identifying and quantifying airborne insects.
  • Rodrigo Alvarez-Icaza, founder and CEO of Elysium Robotics, a company that's replacing electric motors with muscle-like actuators to enable massive deployment of highly capable and low-cost robotic systems.
  • Blake Herren, CEO and Co-founder of Raven Space Systems, which is modernizing composite manufacturing with 3D printing and Industry 4.0 solutions to build the factories of the future.

------

This article originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston geothermal unicorn Fervo officially files for IPO

going public

Fervo Energy has officially filed for IPO.

The Houston-based geothermal unicorn filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission on April 17 to list its Class A common stock on the Nasdaq exchange. Fervo intends to be listed under the ticker symbol "FRVO."

The number and price of the shares have not yet been determined, according to a news release from Fervo. J.P. Morgan, BofA Securities, RBC Capital Markets and Barclays are leading the offering.

The highly anticipated filing comes as Fervo readies its flagship Cape Station geothermal project to deliver its first power later this year

"Today, miles-long lines for gasoline have been replaced by lines for electricity. Tech companies compete for megawatts to claim AI market share. Manufacturers jockey for power to strengthen American industry. Utilities demand clean, firm electricity to stabilize the grid," Fervo CEO Tim Latimer shared in the filing. "Fervo is prepared to serve all of these customers. Not with complex, idiosyncratic projects but with a simplified, standardized product capable of delivering around-the-clock, carbon-free power using proven oil and gas technology."

Fervo has been preparing to file for IPO for months. Axios Pro first reported that the company "quietly" filed for an IPO in January and estimated it would be valued between $2 billion and $3 billion.

Fervo also closed $421 million in non-recourse debt financing for the first phase of Cape Station last month and raised a $462 million Series E in December. The company also announced the addition of four heavyweights to its board of directors last week, including Meg Whitman, former CEO of eBay, Hewlett-Packard, and Spring-based HPE.

Fervo reported a net loss of $70.5 million for the 2025 fiscal year in the S-1 filing and a loss of $41.1 million in 2024.

Tracxn.com estimates that Fervo has raised $1.12 billion over 12 funding rounds. The company was founded in 2017 by Latimer and CTO Jack Norbeck.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

New UT Austin med center, anchored by MD Anderson, gets $1 billion gift

Future of Health

A donation announced Tuesday, April 21, breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release.

The release also records "significant support" for undergraduate scholarships, student housing, and the Texas Advanced Computing Center for supercomputing research.

Both the new research campus and the UT Dell Medical Center will integrate advanced computing into their research and practices. At the medical center, the university hopes that will lead to "earlier detection, more precise and personalized care, and better health outcomes." The University of Texas MD Anderson Cancer Center will also be integrated into the new medical center.

That comes with a numeric goal measured in 10s: raise $10 billion and rank among the top 10 medical centers in the U.S., both in the next decade.

In the shorter term, the university will break ground on the medical center with architecture firm Skidmore, Owings & Merrill (SOM) "later this year."

“UT Austin, where Dell Technologies was founded from a dorm room, has always been a place where bold ideas become real-world impact,” said Michael and Susan Dell in a joint statement.

They continued, “What makes this moment so meaningful is the opportunity to build something that brings every part of the journey together — from how students learn, to how discoveries are made, to how care reaches families. By bringing together medicine, science and computing in one campus designed for the AI era, UT can create more opportunity, deliver better outcomes, and build a stronger future for communities across Texas and beyond.”

This is the second major gift this year for the planned multibillion-dollar medical center. In January, Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed $100 million$100 million.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

Alzheimer’s research

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March.

Dr. Ryan S. Dhindsa is an assistant professor of pathology & immunology at Baylor and a principal investigator at Texas Children’s Duncan Neurological Research Institute (Duncan NRI). He hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation.

“It is an honor to receive this support from the Cure One, Cure Many Award. Viral infections are emerging as a major, underappreciated driver of Alzheimer's disease, and this award will allow our team to conduct the most comprehensive screen of viral exposures and host genetics in Alzheimer's to date, spanning over a million individuals,” Dhindsa said in a news release. “Our goal is to identify which viruses matter most, why some people are more vulnerable than others, and ultimately move the field closer to new therapeutic strategies for patients.”

Roughly 150 million people worldwide will suffer from Alzheimer’s by 2050, making it the most common cause of dementia in the world. Despite this, scientists are still at a loss as to what exactly causes it.

Dhindsa’s research is part of a new range of theories that certain viral infections may trigger Alzheimer’s. His team will take a two-fold approach. First, they will analyze the medical records of more than a million individuals looking for patterns. Second, they will analyze viral DNA in stem cell-derived brain cells to see how the infections could contribute to neurological decay. The scale of the genomic data gathering is unprecedented and may highlight a link that traditional studies have missed.

Also joining the project are Dr. Caleb Lareau of Memorial Sloan Kettering Cancer Center and Dr. Artem Babaian of the University of Toronto. Should a link be found, it would open the door to using anti-virals to prevent or treat Alzheimer’s.

View All Listings